BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NYSE:BHVN) 6/18/19 $300.0 $2,209.0 $2,244.7 2% Ampio Pharmaceuticals Inc. (NASDAQ:AMPE) 6/17/19 $12.0 $56.6 $55.1 -3% Sellas...
BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...University and was previously CMO, EVP and head of R&D of Galena Biopharma Inc., now Sellas Life Sciences Group Ltd....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...as SVP, general counsel. He was general counsel of Galena Biopharma Inc., which merged with Sellas...
BioCentury | Apr 6, 2018
Clinical News

Sellas reports Phase IIb TNBC data for NeuVax combo

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...The single-blind, U.S., investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...
BioCentury | Apr 2, 2018
Clinical News

Sellas rises on Phase IIb TNBC data

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...IHC). The single-blind, investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...
BioCentury | Dec 15, 2017
Clinical News

Sellas reports Phase II data for galinpepimut-S in MM

...In September, Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) reported data from 20 patients with multiple myeloma (MM) in a...
...is a vaccine comprising WT1 peptides administered in combination with an adjuvant and immune modulator. Sellas Life Sciences Group Ltd....
...survival (DFS), overall survival (OS), safety and WT1 expression Status: Phase II data Milestone: NA Claire Quang galinpepimut-S Sellas Life Sciences Group Ltd. Wilms...
BioCentury | Dec 1, 2017
Company News

Sellas, Merck to collaborate on Phase I/II trial in cancer

...Sellas Life Sciences Group Ltd., Hamilton, Bermuda Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Jennie Walters galinpepimut-S Keytruda Merck & Co. Inc. Sellas...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...named Jonathan Eckard chief scientific affairs officer. He was chief business and strategy officer of Sellas...
BioCentury | Aug 11, 2017
Company News

Sellas finds public path

...Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S ( WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...
BioCentury | Aug 8, 2017
Company News

Sellas find public path

...form Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S (WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...
Items per page:
1 - 10 of 21
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NYSE:BHVN) 6/18/19 $300.0 $2,209.0 $2,244.7 2% Ampio Pharmaceuticals Inc. (NASDAQ:AMPE) 6/17/19 $12.0 $56.6 $55.1 -3% Sellas...
BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...University and was previously CMO, EVP and head of R&D of Galena Biopharma Inc., now Sellas Life Sciences Group Ltd....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...as SVP, general counsel. He was general counsel of Galena Biopharma Inc., which merged with Sellas...
BioCentury | Apr 6, 2018
Clinical News

Sellas reports Phase IIb TNBC data for NeuVax combo

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...The single-blind, U.S., investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...
BioCentury | Apr 2, 2018
Clinical News

Sellas rises on Phase IIb TNBC data

...in the relative risk of recurrence vs. the control arm in the 98-patient TNBC cohort. Sellas...
...in TNBC and plans to advance NeuVax's development through a partnership or other strategic collaboration. Sellas...
...IHC). The single-blind, investigator-sponsored trial enrolled 275 patients overall with node-positive breast cancer or TNBC. Sellas...
BioCentury | Dec 15, 2017
Clinical News

Sellas reports Phase II data for galinpepimut-S in MM

...In September, Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) reported data from 20 patients with multiple myeloma (MM) in a...
...is a vaccine comprising WT1 peptides administered in combination with an adjuvant and immune modulator. Sellas Life Sciences Group Ltd....
...survival (DFS), overall survival (OS), safety and WT1 expression Status: Phase II data Milestone: NA Claire Quang galinpepimut-S Sellas Life Sciences Group Ltd. Wilms...
BioCentury | Dec 1, 2017
Company News

Sellas, Merck to collaborate on Phase I/II trial in cancer

...Sellas Life Sciences Group Ltd., Hamilton, Bermuda Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Jennie Walters galinpepimut-S Keytruda Merck & Co. Inc. Sellas...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...named Jonathan Eckard chief scientific affairs officer. He was chief business and strategy officer of Sellas...
BioCentury | Aug 11, 2017
Company News

Sellas finds public path

...Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S ( WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...
BioCentury | Aug 8, 2017
Company News

Sellas find public path

...form Sellas Life Sciences Group Inc. The combined company's pipeline will include galinpepimut-S (WT1 vaccine). Sellas...
...of Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas...
...options to monetize its clinical programs, including a sale, merger, reverse merger or combining companies. Sellas...
Items per page:
1 - 10 of 21